| Biotechnology Industry | Healthcare Sector | Mr. Nan Gui Cai CEO | XSHE Exchange | CNE1000032S5 ISIN |
| CN Country | 514 Employees | 28 Jun 2024 Last Dividend | 16 Jul 2020 Last Split | - IPO Date |
Sailong Pharmaceutical Group Co., Ltd. is at the forefront of the pharmaceutical industry in China, specializing in the research, development, production, marketing, and servicing of pharmaceutical intermediates, raw materials, and preparations. The company encompasses a broad range of products that cater to various therapeutic areas, including cardiovascular, cerebrovascular, neurological, and digestive system ailments, as well as proton pump inhibitors, anti-infectives, anti-bleeding drugs, and analgesics. Initially known as Zhuhai Sailong Pharmaceutical Co.,Ltd., it underwent a rebranding in September 2021 to Sailong Pharmaceutical Group Co., Ltd. Since its establishment in 2002, the company has established its headquarters in Zhuhai, China, signifying its strategic positioning within the Chinese pharmaceutical industry.
The Sailong Pharmaceutical Group Co., Ltd. portfolio encompasses a wide range of pharmaceutical products and services aimed at addressing a variety of health conditions and therapeutic needs: